ABVX:EPA
Abivax SA
€77.15
arrow_downward
-0.64%(-0.50) 1D
Nov 6, 5:36:06 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€74.45
High
€77.15
Low
€73.80
Mkt. cap
6.84B
Avg. vol.
111.44K
Volume
161.37K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
Open
€74.45
High
€77.15
Low
€73.80
Mkt. cap
6.84B
Avg. vol.
111.44K
Volume
161.37K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
Coinpaper
·
6 minutes ago
S&P 500 Earnings Beats Shrink to Just 2.7%, Weakest in Four Years Despite 84% of Companies Topping Forecasts
FXLeaders
·
33 minutes ago
Dow Jones Futures Rise as Nasdaq Futures Fall on Microsoft-Oracle News
Binance
·
2 hours ago
TradFi News | Nasdaq Drops 3.4% in Week as AI Chip Stocks Slump; Berkshire Posts Record $9.6 Billion Buyback
Yahoo Finance
·
6 hours ago
UnitedHealth (UNH): A Dow Stock for 2027 Where the Margin Repair Is Starting to Show
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteabivax.com